ACCEL-LOADING-ACS Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether adjunctive cilostazol loading/maintenance to standard treatment (aspirin, clopidogrel, and statin) is effective in reduction of major adverse cardiovascular events, platelet activation, inflammation and myonecrosis in patients with non-ST-elevation acute coronary syndrome (ACS)undergoing percutaneous coronary intervention (PCI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Residual Platelet Activity Despite Aspirin Utilization in Coronary Heart Disease

NCT01820429

Coronary Heart Disease Non ST-elevation Acute Coronary Syndromes

COMPLETED

Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions

NCT05732701

Percutaneous Coronary Intervention Platelet Aggregation Inhibitors Coronary Artery Disease

RECRUITING NA

Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome

NCT05577988

MYOCARDIAL INFARCTION

RECRUITING PHASE3

The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent

NCT00418860

Coronary Artery Disease

COMPLETED NA

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

NCT02293395

Acute Coronary Syndrome

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In ACS patients, platelet activation, inflammation, and ischemia-reperfusion injury can be closely associated with the risk of post-PCI myonecrosis and ischemic events occurrence. In the ACCEL-AMI (Adjunctive Cilostazol versus high maintenance-dose ClopidogrEL in patients with Acute Myocardial Infarction)study, adjunctive cilostazol increased platelet inhibition compared with double-dose clopidogrel. Meanwhile, statins can reduce the extent of myonecrosis via limiting inflammation and myocardial infarct size by activating phosphatidylinositol-3-kinase (PI3K), ecto-5'-nucleotidase, Akt/endothelial nitric oxide synthase (eNOS), and the downstream effectors inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Inhibition of PI3K, adenosine receptors, eNOS, iNOS, or COX-2 abrogates the protective effects of statins. In animal study, the combination of low-dose statin with cilostazol synergistically limits infarct size. Multiple studies have shown that cilostazol can influence inflammation and RISK pathway using the similar pathway with statin. This study will be performed to evaluate the role of adjunctive cilostazol in platelet inhibition, inflammation, and myonecrosis compared with standard treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Platelet Aggregation Inhibitors Anti-inflammatory Agent Myocardial Reperfusion Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DAPT

Group Type ACTIVE_COMPARATOR

Dual Anti-Platelet Therapy (DAPT)

Intervention Type DRUG

* Loading: aspirin 300mg + clopidogrel 600mg
* Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month

TAPT

Group Type EXPERIMENTAL

Triple Anti-Platelet Therapy (TAPT)

Intervention Type DRUG

* Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg
* Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dual Anti-Platelet Therapy (DAPT)

* Loading: aspirin 300mg + clopidogrel 600mg
* Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month

Intervention Type DRUG

Triple Anti-Platelet Therapy (TAPT)

* Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg
* Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* at least 18 years of age
* Non-ST-elevation ACS patients undergoing PCI within 48 hours after hospitalization

Exclusion Criteria

* ST segment elevation acute myocardial infarction
* NSTE ACS with high-risk features warranting emergency coronary angiography
* Oral anticoagulation therapy with warfarin
* Use of pre-procedural glycoprotein IIb/IIIa inhibitor
* Contraindication to antiplatelet therapy
* AST or ALT ≥ 3 times upper normal
* Left ventricular ejection fraction \< 30%
* WBC \< 3,000/mm3, platelet \< 100,000/mm3
* Creatinine ≥ 3 mg/dl
* stroke within 3 months

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No